Senologie - Zeitschrift für Mammadiagnostik und -therapie 2020; 17(02): e46
DOI: 10.1055/s-0040-1710740

IMPACT - Implementing Patients’ Competence in Oral Breast Cancer Therapy - a randomized, controlled study of standardized patient coaching versus patient management according to local practice for patients with HR positive HER2 negative metastatic breast cancer treated with Abemaciclib

M Welslau
1  Hämato-Onkologische Schwerpunktpraxis am Klinikum Aschaffenburg, Aschaffenburg, Deutschland
N Nabieva
2  Erlangen University Hospital, Department of Gynecology and Obstetrics, Erlangen, Deutschland
3  Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Erlangen, Deutschland
T Decker
4  Gemeinschaftspraxis für Hämatologie und Onkologie GbR Ravensburg, Ravensburg, Deutschland
E Belleville
5  ClinSol GmbH & Co. KG, Würzburg, Deutschland
O Knapp
5  ClinSol GmbH & Co. KG, Würzburg, Deutschland
H Lothar
3  Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Erlangen, Deutschland
P Fasching
6  Institut für Frauengesundheit GmbH (IFG) Erlangen, Erlangen, Deutschland
H Tesch
7  Centrum für Hämatologie und Onkologie Bethanien Frankfurt, Frankfurt am Main, Deutschland
› Author Affiliations

Purpose Oral agents, like CDK4/6 inhibitors, provide an attractive approach for the treatment of metastatic breast cancer. However, this type of therapy requires a high level of self-management competence by the patient. The non-interventional study (NIS) IMPACT intends to evaluate the effectiveness of a standardized patient education and coaching for therapy management provided by specially trained oncology nurses regarding persistence rate, side effects management and unplanned therapy interruptions in outpatient oncology care for patients under Abemaciclib treatment.

Methods 212 Patients with HR+, HER2- metastatic breast cancer who are treated with Abemaciclib according to clinical routine will be enrolled in approx. 30 sites. Patients will be randomized to standardized patient coaching (based on MOATT©) or patient management according to local practice, respectively. Follow up is documented for a maximum of 24 weeks.

Results Data of 212 MBC patients regarding a potential effect of standardized patient coaching on the persistence rate after 24 weeks of Abemaciclib therapy will be presented. Quality of live data as well as data regarding patient reported self-efficacy, side-effects, health related stress and therapy related knowledge will be presented.

Conclusions The effectiveness of standardized patient coaching is observed and analyzed in a real-world setting to understand its benefits for MBC patients under Abemaciclib treatment with regard to therapy adherence and patient self-management competence.

Publication History

Publication Date:
24 June 2020 (online)

© Georg Thieme Verlag KG
Stuttgart · New York